TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancerGeoffrey R. Oxnard, Myung‐Ju Ahn, Helena A. Yu et al.|Annals of Oncology|2020Cited by 443
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated TranscriptionMelanie M. Frigault, Ahmed Hamdy|Cancer Research Communications|2023Cited by 16